

ACURA PHARMACEUTICALS, INC  
Form 8-K  
March 15, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D. C. 20549**

---

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act Of 1934**

**March 15, 2007**  
Date of Report (Date of earliest event reported)

---

**ACURA PHARMACEUTICALS, INC.**  
(Exact Name of Registrant as Specified in Charter)

---

**State of New York**  
(State of Other Jurisdiction  
of Incorporation)

**1-10113**  
(Commission File Number)

**11-0853640**  
(I.R.S. Employer  
Identification Number)

**616 N. North Court, Suite 120**  
**Palatine, Illinois 60067**  
(Address of principal executive offices) (Zip Code)

**(847) 705-7709**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e- 4(c))
-

**Item 8.01 Other Events**

On March 15, 2007, the Registrant issued a press release updating its OxyADF tablets development program and results of Study AP-ADF-102. A copy of the press release is attached as Exhibit 99.1 hereto.

**Item 9.01 Financial Statements and Exhibits.**

**Exhibit**

**Number**

**Description**

99.1 Press Release dated March 15, 2007 Updating OxyADF Tablets Development Program and Results of Study AP-ADF-102.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**ACURA PHARMACEUTICALS, INC.**

By: /s/ Peter A. Clemens

---

Peter A. Clemens  
Senior Vice President & Chief Financial Officer

Date: March 15, 2007

---

**EXHIBIT INDEX**

**Exhibit  
Number**

**Description**

99.1 Press Release dated March 15, 2007 Updating OxyADF Tablets Development Program and Results of Study AP-ADF-102

---